Drugmakers unveil potential alternatives to Januvia

06/8/2008 | Bloomberg11

Companies developing a new class of diabetes drugs known as DPP-4 inhibitors have presented possible alternatives to Januvia, an FDA-approved treatment from Merck & Co., at the American Diabetes Association meeting. Researchers said that saxagliptin, Bristol-Myers Squibb Co. and AstraZeneca's candidate, helped more than one-third of patients reach the recommended glucose level in a six-month study. A combination of Takeda Pharmaceutical Co.'s alogliptin and Actos, an older drug, reduced glucose levels better than placebo and seemed as effective as Januvia, analysts said.

View Full Article in:

Bloomberg11

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA